Table of Contents
`This paper gives a review of the study of cannabis use, cannabis dependence, and its treatment. Cannabis is the most popular illegal substance globally. Early use and normalization of that use have been recognized as specific hazard factors for later dangerous cannabis (and other medication) use, impact on psychological wellness, lower instructive accomplishment, and overall development, according to a scope of studies. It is proven that around one out of ten individuals who had ever utilized cannabis will turn out to be dependent on these odds increase with recurrence of experimentation with the substance. There have been studies in the extent of success for treatment for cannabis use. There are so far no proof based pharmacotherapies accessible for the effects of cannabis withdrawal and needs or cravings for the substance. CBT and a risk assessment and reduction have the most grounded proof of progress, and organized, family-based intervention, done in conjunction with the above gives powerful treatment alternatives to young people (Hasin, et al., 2017).
However, cannabis use has increased in the face of federal control in state-controlled legislatures. The legalization of the cannabis state increased the need for cultivation, the development of strong strains, and increased competition in the cannabis supply industry. The use and promotion of cannabis legalization is promoted because of any potential health benefits and health problems that have not been proven to be true.
Cannabis abuse, including details of continued cannabis use despite a lack of mental, physical or social activity. It is an old medical definition used before the “Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)” that distinguishes substance use from substance dependence. The “Diagnostic and Mental Disorder Statistics Manual (DSM-5)” is a modification of the marijuana disorder situation determined by nine pathological patterns classified by disability control, social disability, risky behavior, or physiological adaptation. This activity will focus on marijuana abuse and related substances - intoxication and withdrawal and marijuana use disorders (Gates, et al., 2016).
History and Physical
Once evaluated, a history of drug use, mental health, family history of drug use and mental health disorders, medical history, asthma, drug use in social circles (especially during adolescence) and environmental stress should be examined.
The situation is an important part of the psychological test and it may indicate marijuana use. Drunkenness can include nausea, anxiety, uncontrolled laughter, loss of appetite, apathy, forgetfulness, restlessness, tachycardia, conjunctival injections, and dry mouth. And less common may include confusion, confusion, and perception. Prolonged use or delay usually results in apathy, lack of motivation, boredom, lack of interest in general actions, difficulty concentrating, and isolation. Knowledge can be quickly assessed by looking for a short fictional story from state tests) in chronic depression and major fatigue disorder In substance use and mood disorder or anxiety is certainly not exclusive and often occurs simultaneously. Even suicidal ideation and suicidal tendencies can cause mood swings, stress or the use of new substances. It is necessary to know the severity and intensity of the symptoms of the difference; Persistent symptoms of tenderness may indicate comorbid early mental illness disorders.
The classification of cannabis use in the United States is determined by DSM-5. Generally, it is understood as an acute and long-lasting effect. Acute stages include intoxication and withdrawal - minor complications including complacency, psychosis, anxiety and insomnia. The use of chronic routines can be characterized by chaotic actions. When considering settings (such as emergency departments, office visits, or rehabilitation programs), different effects of marijuana can be considered (Olfson, et al., 2018).
`Marijuana is an often-overlooked addiction because popular opinion puts forth the idea that one cannot get addicted to the substance, but studies have proven this to be a misconception, however, most studies call it marijuana dependence instead of addiction, which has differences in how it affects the person abusing the drug physical and mentally. Studies have also been done on the effects of Marijuana dependence, which leads one to become dependent on the substance, the prevalence of dependency, and potential treatments.
Marijuana has a host of adverse effects that naturally occur from short term use as well as abuse of the substance. One study state that short-term marijuana use can lead to impaired short-term memory development, impaired motor coordination, and altered judgment. Long term, heavy use of marijuana can lead to addiction, this occurs in 9% of users. Altered brain development, lowered school or work performance, cognitive impairment including lowered IQ if use began in adolescence, Diminished life satisfaction, symptoms usually associated with Chronic Bronchitis, and increased risk of psychosis.
Research shows that the stays in a condition of dynamic, experience-guided growth from the pre-birth period through youth and the teenage years until the time of around 21 years. During these formative periods, it is characteristically more helpless than a developed brain to the impacts of certain substances, for instance, tetrahydrocannabinol, or THC, the part of marijuana that results in "getting high". This view is supported by studies done on animals, which have proven, for instance, that pre-birth or infant introduction to THC can recalibrate the functioning of the reward framework to other drugs and that pre-birth presentation meddles with "cytoskeletal elements", which are basic for the foundation of axonal associations between neurons.
In comparison to unexposed controls, those who smoked marijuana consistently during puberty have fewer neurons in certain parts of the rain. This includes the precuneus, a key hub that is associated with capacities that require a high level of conscious thought and alertness, and the fimbria, a part of the hippocampus that is imperative in learning and memory. Decreased neuron capacity has additionally been seen in the prefrontal systems in charge of executive functions such as inhibitory control and the subcortical systems, which process propensities and schedules. In addition, imaging studies in people who use cannabis have uncovered diminished activity in prefrontal locales and decreased growth in the hippocampus. Thus, certain brain areas might be more susceptible than others to the impacts of marijuana usage (Cougle, et al., 2011).
The negative impact of marijuana use on the neural fibers of the brain is especially obvious if the use begins in the teenage or early adult years, which may clarify the finding of a relationship between using marijuana from youth into adulthood and noteworthy decreases in IQ. The deficits in a brain network related to introduction to marijuana in youth are supported by studies that show that the cannabinoid system has a meaningful impact on synapse formation.
Marijuana is one of the most widely abused illicit drugs in the world, with a subset of marijuana smokers engaging day by day use and dependence. Among American secondary school understudies, 20% of the individuals who report consistently smoking marijuana are everyday smokers Although the probability of advancing from periodic marijuana use to everyday marijuana use is lower than it is for other substances, for example, nicotine, cocaine, or heroin the sheer number of people who use marijuana ensures that a large number will become dependent on it Some marijuana smokers look for treatment for their marijuana use because they report being disappointed with their overwhelming marijuana use and think that it is hard to stop without outside help. For instance, even the individuals who look for treatment frequently do not accomplish continued sobriety (Van Winkel, et al., 2011).
In Australia, 7% of a longitudinal study met criteria for cannabis dependence, with the indications reported being persevering need to smoke (91%), inadvertent use (84%), and withdrawal side effects (74%). A considerable number of those asked (38%) revealed utilizing marijuana to lighten withdrawal. A low rate (9%) of those with cannabis dependence additionally met criteria for liquor reliance, demonstrating that cannabis and liquor reliance have low rates of comorbidity. In the United States, rates of marijuana misuse and dependence have risen. Among people who announced smoking marijuana inside the previous year, rates of marijuana misuse or reliance expanded from 30.2% (2010 to 2015) to 35.6% (2018 to 2019). Contributing elements may incorporate the accessibility of more potent marijuana and starting marijuana use in one's youth. marijuana laws seem to have added to the expanded commonness of illegal cannabis use and cannabis use disorder
Like other substance abuse disorders, cannabis use is not effectively treated by psychosocial intervention programs in out‐patient settings. CBT in the group and MET in individual sessions were the most reliably investigated methods; they have exhibited better results over control conditions. Specifically, the above treatments were reliably viable over no treatment in lessening the recurrence of cannabis use with nine trials demonstrating better results and four indicating practically identical results, how much was used per one sitting, with seven trials demonstrating better results and two indicating equivalent results, and seriousness of reliance with seven studies demonstrating better results and two demonstrating similar results. Conversely, psychosocial treatment was not significantly better than no treatment in improving cannabis‐related issues with four trials indicating better results and seven demonstrating practically identical results, inspiration to stop, without any trials demonstrating improved results and three indicating similar results, other substance use without any trials indicating better results and seven demonstrating similar results or psychological well-being without any investigations indicating predominant results and five indicating equivalent results.
A research conducted by Van Winkel, et al., (2011), Examination of studies detailing intervention treatment gains was possible for a subset of trials that included short term follow up of roughly four months. This investigation found that those getting any mediation revealed fewer periods of substance use, smoked less every day, and had fewer side effects of dependence and fewer cannabis‐related issues overall. High‐intensity interventions of multiple sessions and those done over periods longer than one month, especially MET + CBT mediations, were best. Along with that, mediations were finished as expected by the majority of members. Remarkably, three examinations researched the adequacy of psychosocial mediation contrasted and treatment as regular conveyed at mental out‐patient focuses and announced little proof of huge gathering contrasts in treatment results. At last, results from six trials, which included the possibility the board assistant medicines, were blended however recommended that reductions in cannabis use recurrence and seriousness of reliance were likely when joined with CBT or with MET + CBT.
The goal is to increase the multi-functional and multifactorial functions of individual functions. Supportive care may be provided during detoxification; enabling access to psychiatric services allows resolving underlying disorders; Psychological counseling can change behavior, develop healthy coping skills during stress and provide mood insights.
As the cannabis wound becomes stronger and more accessible, the risk of the frequency and severity of serious adverse reactions increases. The drug should be discontinued for the purpose of those who are addicted or withdrawal, or use marijuana. A gradual reduction as opposed to a sudden shutdown will reduce back discomfort and prevent re-infection. Cannabis addiction often does not require treatment management and will remain self-limiting. Pharmaceutical detoxification is still under investigation. Systematic reviews indicate that most studies are preliminary and do not support statistical clinical considerations due to their small size, inconsistency, and risk of attracting bias. There is no FDA-approved drug for the treatment of cannabis use disorders. Tetrahydrocannabinol treatment shows some possibilities but more information about its validity and dosage, duration, composition and combination therapy is required. Gabapentin and N-acetylcysteine are also used but have vague advantages. Another ingredient in cannabis, cannabidiol, promises to alter serotonergic, glutamatergic and endocannabinoid systems (Baker, Hides, & Lubman, 2010).
It is important for all specialized suppliers to be aware of the effects of cannabis use. It is becoming commonplace everywhere in society. Evidence to support the use of cannabis for certain conditions is limited and in many cases, isolated researchers obtained from THC's pharmaceutical preparation to raise funds for this study due to the Food and Drug Administration. Granted access does not limit limited use. Distributors can influence the tensions, dosages, compositions and indicators used based on feedback. It should also be emphasized that continued use and / or heavy cannabis use may increase the risk of intoxication or withdrawal that requires treatment and that long-term complications may be irreversible. Although the use of opium, benzodiazepines, and alcohol is comparable, it is still a substance that can potentially affect its health and cause social and functional activity. By spreading their evidence-based use, it is important to distinguish cannabis abuse from all historical use. Differences in state regulations governing the medical indication of cannabis should be considered. And suppliers should not forget that the treatment cannabis is strictly regulated by the pharmaceutical industry and is not scientifically justifiable - it is produced by many operations without the same supervision and in situations that in most cases are not based on strict medical or scientific evidence (Di Forti, et al., 2019).
Baker, A. L., Hides, L., & Lubman, D. I. (2010). Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. The Journal of clinical psychiatry, 71(3), 247-254.
Cougle, J. R., Bonn-Miller, M. O., Vujanovic, A. A., Zvolensky, M. J., & Hawkins, K. A. (2011). Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychology of Addictive Behaviors, 25(3), 554.
Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., ... & La Barbera, D. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. The Lancet Psychiatry, 6(5), 427-436.
Gates, P. J., Sabioni, P., Copeland, J., Le Foll, B., & Gowing, L. (2016). Psychosocial interventions for cannabis use disorder. Cochrane Database of Systematic Reviews, (5).
Hasin, D. S., Sarvet, A. L., Cerdá, M., Keyes, K. M., Stohl, M., Galea, S., & Wall, M. M. (2017). US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991-1992 to 2012-2013. Jama Psychiatry, 74(6), 579-588.
Olfson, M., Wall, M. M., Liu, S. M., & Blanco, C. (2018). Cannabis use and risk of prescription opioid use disorder in the United States. American Journal of Psychiatry, 175(1), 47-53.
Van Winkel, R., Van Beveren, N. J., & Simons, C. (2011). AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology, 36(12), 2529-2537.
Remember, at the center of any academic work, lies clarity and evidence. Should you need further assistance, do look up to our Nursing Assignment Help
Proofreading and Editing$9.00Per Page
Consultation with Expert$35.00Per Hour
Live Session 1-on-1$40.00Per 30 min.
Doing your Assignment with our resources is simple, take Expert assistance to ensure HD Grades. Here you Go....